Document is current
Any future updates will be listed below
-
Authors
Boudewijns, Steve http://orcid.org/0000-0003-4201-3507
Bloemendal, Martine http://orcid.org/0000-0001-9395-4214
de Haas, Nienke http://orcid.org/0000-0002-4082-0498
Westdorp, Harm http://orcid.org/0000-0002-3336-4164
Bol, Kalijn F. http://orcid.org/0000-0003-4165-2040
Schreibelt, Gerty http://orcid.org/0000-0002-0156-8365
Aarntzen, Erik H. J. G. http://orcid.org/0000-0002-3809-0182
Lesterhuis, W. Joost http://orcid.org/0000-0002-2718-276X
Gorris, Mark A. J. http://orcid.org/0000-0003-3621-226X
Croockewit, Alexandra
van der Woude, Lieke L.
van Rossum, Michelle M.
Welzen, Marieke
de Goede, Anna
Hato, Stanleyson V.
van der Graaf, Winette T. A.
Punt, Cornelis J. A. http://orcid.org/0000-0003-0846-1445
Koornstra, Rutger H. T. http://orcid.org/0000-0002-5446-755X
Gerritsen, Winald R. http://orcid.org/0000-0003-1110-9119
Figdor, Carl G. http://orcid.org/0000-0002-2366-9212
de Vries, I. Jolanda M. http://orcid.org/0000-0002-8653-4040
-
Funding
Funding for this research was provided by:
Dutch Cancer Society (KWF 2009-4402)
Netherlands Organisation for Scientific Research (918.14.655)
- License Information
-
More Information
Article History
Received: 12 July 2019
Accepted: 28 December 2019
First Online: 24 January 2020
Compliance with ethical standards
:
: Winald R. Gerritsen received speaker fees from Astellas, Bayer, Merck Sharp & Dohme (MSD) and European Society for Medical Oncology, participated in advisory boards of Amgen, Bayer, Bristol-Myers Squibb (BMS), Curevac, Dendreon, IQVIA, Janssen-Cilag, MSD, Morphosys and Sanofi, and received research grants from Astellas, Amgen, Bayer, Janssen-Cilaq and Sanofi. Rutger H. T. Koornstra has received speaker fees from BMS, MSD and Roche. He has advisory relationships for BMS, MSD, Novartis and Roche. He received research grants from BMS and Roche. W. Joost Lesterhuis received research funding from Douglas Pharmaceuticals and Astra Zeneca. The authors declare that there are no other conflicts of interest.
: All procedures performed in this trial were in concordance with the ethical standards of the institution and the 1964 Helsinki Declaration and its later amendments. The trial was approved by the Dutch Central Committee on Research Involving Human Subjects (study approval number: NL32381.000.10) and registered as NCT02285413 at ClinicalTrials.gov.
: Prior to inclusion, written informed consent to experimental treatment and analysis of data and tissue to answer research questions directly related to the trial was obtained from all patients.
